Literature DB >> 16684603

136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands.

M M Reilly1, P de Jonghe, D Pareyson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16684603     DOI： 10.1016/j.nmd.2006.03.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  13 in total

1.  Natural history of Charcot-Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life.

Authors:  Luca Padua; D Pareyson; I Aprile; T Cavallaro; D A Quattrone; N Rizzuto; G Vita; P Tonali; A Schenone
Journal:  Neurol Sci       Date:  2009-12-17       Impact factor: 3.307

2.  High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.

Authors:  Richard A Lewis; Michael P McDermott; David N Herrmann; Ahmet Hoke; Lora L Clawson; Carly Siskind; Shawna M E Feely; Lindsey J Miller; Richard J Barohn; Patricia Smith; Elizabeth Luebbe; Xingyao Wu; Michael E Shy
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

Review 3.  Mechanisms and Treatments in Demyelinating CMT.

Authors:  Vera Fridman; Mario A Saporta
Journal:  Neurotherapeutics       Date:  2021-11-08       Impact factor: 6.088

4.  Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation.

Authors:  Elena Gallardo; Kristl G Claeys; Eva Nelis; Antonio García; Ana Canga; Onofre Combarros; Vincent Timmerman; Peter De Jonghe; José Berciano
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

5.  Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.

Authors:  Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik
Journal:  BMC Med       Date:  2009-11-12       Impact factor: 8.775

6.  Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study.

Authors:  L Padua; I Aprile; T Cavallaro; I Commodari; D Pareyson; A Quattrone; N Rizzuto; G Vita; P Tonali; A Schenone
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

Review 7.  Experimental therapeutics in hereditary neuropathies: the past, the present, and the future.

Authors:  David N Herrmann
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

9.  Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Authors:  Davide Pareyson; Mary M Reilly; Angelo Schenone; Gian Maria Fabrizi; Tiziana Cavallaro; Lucio Santoro; Giuseppe Vita; Aldo Quattrone; Luca Padua; Franco Gemignani; Francesco Visioli; Matilde Laurà; Davide Radice; Daniela Calabrese; Richard A C Hughes; Alessandra Solari
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

Review 10.  Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.

Authors:  Burkhard Gess; Jonathan Baets; Peter De Jonghe; Mary M Reilly; Davide Pareyson; Peter Young
Journal:  Cochrane Database Syst Rev       Date:  2015-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.